A new share structure is meant to beef up Lundbeck for future acquisitions, the company and its majority owner the Lundbeck Foundation say. The proposal has nevertheless been met with criticism from shareholders who fear dilution. On Wednesday, Lundbeck will meet its critics.
by ANDREAS LØNSTRUP, translated by daniel pedersen
A steadily decreasing share price and strong criticism from its base are the backdrop for Lundbeck’s annual general meeting on Wednesday.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.